Bergapten, an LXR agonist, impedes the onset and progression of HCC by regulating the LXR/PI3K/Akt and LXR/IDOL/LDLR pathways and decreasing LDLR expression in a dose-dependent manner 254. This evidence concerns the gene LDLR and hepatocellular carcinoma.